{"id":"teriparatide-pen-injector","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions (erythema, pain, swelling)"},{"rate":"8-15","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Hypercalcemia"},{"rate":"3-8","effect":"Leg cramps"}]},"_chembl":{"chemblId":"CHEMBL1201549","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teriparatide mimics the action of endogenous parathyroid hormone (PTH) by binding to PTH1 receptors on osteoblasts, promoting bone anabolism and increasing bone mineral density. Unlike continuous PTH exposure which causes bone loss, intermittent administration of teriparatide preferentially stimulates bone formation over resorption, leading to net increases in bone mass and strength.","oneSentence":"Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:44.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women and men at high risk of fracture"},{"name":"Glucocorticoid-induced osteoporosis"}]},"trialDetails":[{"nctId":"NCT03735537","phase":"PHASE4","title":"Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2016-11-01","conditions":"Osteogenesis Imperfecta","enrollment":350},{"nctId":"NCT03133195","phase":"PHASE3","title":"The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2017-05-17","conditions":"Unstable Intertrochanteric Fracture, Pertrochanteric Fracture of Femur, Closed","enrollment":50},{"nctId":"NCT06061354","phase":"PHASE4","title":"Teriparatide on Maxillary Sinus Floor Osseointegration","status":"UNKNOWN","sponsor":"Universidad de Valparaiso","startDate":"2023-08-23","conditions":"Bone Regeneration","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Forsteo","Forteo"],"phase":"marketed","status":"active","brandName":"Teriparatide Pen Injector","genericName":"Teriparatide Pen Injector","companyName":"University of Edinburgh","companyId":"university-of-edinburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling. Used for Osteoporosis in postmenopausal women and men at high risk of fracture, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}